Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23900255 | 1.00 | OPRM1 (0.49) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20858630 | 1.00 | OPRM1 (0.49) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15290736 | 0.97 | OPRM1 (0.46) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20858667 | 0.92 | ALDH1A1 (0.47) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23841245 | 0.92 | ALDH1A1 (0.47) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL723876 | 0.92 | ALDH1A1 (0.47) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12988080 | 0.92 | OPRM1 (0.42) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10928945 | 0.84 | LMNA (0.44) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23841252 | 0.84 | MAPK1 (0.39) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 | |
| Rolziracetam SCHEMBL1159965 | 0.80 | NOTUM (0.47) | OPRM1OPRK1OPRL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119421912-A | Curable resin composition, insulating cured film obtained by curing the composition, insulating cured film for touch panel, and touch panel | 大阪有机化学工业株式会社 | 2025-02-11 | — | — | CN | disclosed |
| CN-119403851-A | Curable resin composition, insulating cured film obtained by curing the composition, insulating cured film for touch panel, and touch panel | 大阪有机化学工业株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-12145139-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-11-19 | — | — | US | disclosed |
| US-11894518-B2 | Electrolytes for stable cycling of high capacity lithium based batteries | IONBLOX, INC. | 2024-02-06 | — | — | US | disclosed |
| WO-2024005195-A1 | CURABLE RESIN COMPOSITION, INSULATING CURED FILM AND INSULATING CURED FILM FOR TOUCH PANEL THAT RESULT FROM CURING SAID COMPOSITION, AND TOUCH PANEL | 大阪有機化学工業株式会社 | 2024-01-04 | — | — | WO | disclosed |
| WO-2024005189-A1 | CURABLE RESIN COMPOSITION, INSULATING CURED FILM AND INSULATING CURED FILM FOR TOUCH PANELS EACH PRODUCED BY CURING SAID COMPOSITION, AND TOUCH PANEL | 大阪有機化学工業株式会社 | 2024-01-04 | — | — | WO | disclosed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-23 | — | — | US | disclosed |
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-23 | — | — | US | disclosed |
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-23 | — | — | US | disclosed |
| US-6942948-B2 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-09-13 | — | — | US | disclosed |
| CN-1215595-C | Nonaqueous electrolyte and secondary battery using the same | MITSUBISHI CHEM CORP (JP) | 2005-08-17 | — | — | CN | disclosed |
| CN-1616576-A | Double-sided pressure-sensitive adhesive tape or sheet and process of producing the same | NITTO DENKO CORP (JP) | 2005-05-18 | — | — | CN | disclosed |
| CN-1201856-C | Stirring arm, stirrer and method of preparing polymer using the stirrer | MITSBISHI RAYON CO LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
| CN-1465117-A | Nonaqueous electrolyte and secondary battery using the same | MITSUBISHI CHEM CORP (JP) | 2003-12-31 | — | — | CN | disclosed |
| EP-1357628-A1 | NONAQUEOUS ELECTROLYTIC LIQUIDS AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-20030165733-A1 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1317013-A1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-06-04 | — | — | EP | disclosed |
| CN-1318426-A | Stirring arm, stirrer and method of preparing polymer using the stirrer | MITSBISHI RAYON CO LTD (JP) | 2001-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | ADH1C, OTC, MLEC | OPRM1 1062/4885OPRK1 2676/4885OPRL1 4294/4885 |
| US-12145139-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | ADH1C, OTC, MLEC | OPRM1 1062/4885OPRK1 2676/4885OPRL1 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.